;PMID: 6252201
;source_file_835.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..176] = [t:47..176]
;2)sentence:[e:177..202] = [t:177..202]
;3)section:[e:206..242] = [t:206..241]
;4)sentence:[e:246..450] = [t:246..450]
;5)sentence:[e:451..689] = [t:451..689]
;6)sentence:[e:690..824] = [t:690..824]
;7)sentence:[e:825..1036] = [t:825..1036]
;8)sentence:[e:1037..1274] = [t:1037..1274]
;9)sentence:[e:1275..1503] = [t:1275..1503]
;10)sentence:[e:1504..1776] = [t:1504..1776]
;11)sentence:[e:1777..1949] = [t:1777..1949]
;12)sentence:[e:1950..2201] = [t:1950..2201]
;13)sentence:[e:2202..2308] = [t:2202..2308]
;14)sentence:[e:2309..2402] = [t:2309..2402]
;15)section:[e:2406..2450] = [t:2406..2449]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:206..242][t:206..241]
;ERROR_Section end mismatch[e:2406..2450][t:2406..2449]
;Token/POS Errors
;ERROR_Token in entity file but not tree[241..242] .
;ERROR_Token in entity file but not tree[2449..2450] ]

;section 0 Span:0..41
;J Biochem (Tokyo). 1980 Aug;88(2):505-16.
(SEC
  (FRAG (JJ:[0..1] J) (NN:[2..9] Biochem) (NN:[10..11] -LRB-)
        (NN:[11..16] Tokyo) (NN:[16..17] -RRB-) (.:[17..18] .)
        (CD:[19..23] 1980) (NNP:[24..27] Aug) (::[27..28] ;) (CD:[28..30] 88)
        (-LRB-:[30..31] -LRB-) (CD:[31..32] 2) (-RRB-:[32..33] -RRB-)
        (::[33..34] :) (CD:[34..37] 505) (::[37..38] -) (CD:[38..40] 16)
        (.:[40..41] .)))

;sentence 1 Span:47..176
;Multiple forms of cytochrome P-450 purified from liver microsomes of 
;phenobarbital- and 3-methylcholanthrene-pretreated rabbits.
;[65..81]:cyp450:"cytochrome P-450"
;[117..130]:substance:"phenobarbital"
;[136..156]:substance:"3-methylcholanthrene"
(SENT
  (NP-HLN
    (NP (JJ:[47..55] Multiple) (NNS:[56..61] forms))
    (PP (IN:[62..64] of)
      (NP (NN:[65..75] cytochrome) (NN:[76..81] P-450)))
    (VP (VBN:[82..90] purified)
      (NP (-NONE-:[90..90] *))
      (PP (IN:[91..95] from)
        (NP
          (NP (NN:[96..101] liver) (NNS:[102..112] microsomes))
          (PP (IN:[113..115] of)
            (NP
              (NP
                (ADJP (NN:[117..130] phenobarbital) (HYPH:[130..131] -)
                  (ADJP-1 (-NONE-:[131..131] *P*)))
                (NML-2 (-NONE-:[131..131] *P*)))
              (CC:[132..135] and)
              (NP
                (ADJP (NN:[136..156] 3-methylcholanthrene) (HYPH:[156..157] -)
                  (ADJP-1 (VBN:[157..167] pretreated)))
                (NML-2 (NNS:[168..175] rabbits))))))))
    (.:[175..176] .)))

;sentence 2 Span:177..202
;II. Spectral  properties.
(SENT
  (NP (LS:[177..179] II) (.:[179..180] .))
  (NP (JJ:[181..189] Spectral) (NNS:[191..201] properties) (.:[201..202] .)))
;ERROR_Sentence has multiple children (TB Error):[177..202]::NP:NP:

;section 3 Span:206..241
;Hashimoto-Yutsudo C, Imai Y, Sato R
(SEC
  (FRAG (NNP:[206..215] Hashimoto) (::[215..216] -) (NNP:[216..223] Yutsudo)
        (NNP:[224..225] C) (,:[225..226] ,) (NNP:[227..231] Imai)
        (NNP:[232..233] Y) (,:[233..234] ,) (NNP:[235..239] Sato)
        (NNP:[240..241] R)))

(ORPH .)

;sentence 4 Span:246..450
;The spectral properties of multiple forms of cytochrome P-450 purified or 
;partially purified from liver microsomes of phenobarbital (PB)- and 
;3-methylcholanthrene (MC)-treated rabbits have been studied.
;[291..307]:cyp450:"cytochrome P-450"
;[365..378]:substance:"phenobarbital"
;[380..382]:substance:"PB"
;[390..410]:substance:"3-methylcholanthrene"
;[412..414]:substance:"MC"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[246..249] The) (JJ:[250..258] spectral)
          (NNS:[259..269] properties))
      (PP (IN:[270..272] of)
        (NP
          (NP (JJ:[273..281] multiple) (NNS:[282..287] forms))
          (PP (IN:[288..290] of)
            (NP
              (NP (NN:[291..301] cytochrome) (NN:[302..307] P-450))
              (VP
                (VP
                  (VP (VBN:[308..316] purified)
                    (NP (-NONE-:[316..316] *)))
                  (CC:[317..319] or)
                  (VP
                    (ADVP (RB:[321..330] partially))
                    (VBN:[331..339] purified)
                    (NP (-NONE-:[339..339] *))))
                (PP (IN:[340..344] from)
                  (NP
                    (NP (NN:[345..350] liver) (NNS:[351..361] microsomes))
                    (PP (IN:[362..364] of)
                      (NP
                        (NP
                          (ADJP
                            (NML
                              (NML (NN:[365..378] phenobarbital))
                              (NML (-LRB-:[379..380] -LRB-) (NN:[380..382] PB)
                                   (-RRB-:[382..383] -RRB-)))
                            (HYPH:[383..384] -)
                            (ADJP-3 (-NONE-:[384..384] *P*)))
                          (NML-1 (-NONE-:[384..384] *P*)))
                        (CC:[385..388] and)
                        (NP
                          (ADJP
                            (NML
                              (NML (NN:[390..410] 3-methylcholanthrene))
                              (NML (-LRB-:[411..412] -LRB-) (NN:[412..414] MC)
                                   (-RRB-:[414..415] -RRB-)))
                            (HYPH:[415..416] -)
                            (ADJP-3 (VBN:[416..423] treated)))
                          (NML-1 (NNS:[424..431] rabbits)))))))))))))
    (VP (VBP:[432..436] have)
      (VP (VBN:[437..441] been)
        (VP (VBN:[442..449] studied)
          (NP-2 (-NONE-:[449..449] *)))))
    (.:[449..450] .)))
;ERROR_Orphan Text from Tree File[241..246] .

;sentence 5 Span:451..689
;Both optical  absorption and EPR studies have shown that the oxidized forms
;of P-450(1),  P-450(2) (from PB-treated animals), and P-450(3) (from
;MC-treated animals) are  in the low spin state, having a Soret absorption
;peak at 417-418 nm.
;[530..538]:cyp450:"P-450(1)"
;[541..549]:cyp450:"P-450(2)"
;[556..558]:substance:"PB"
;[581..589]:cyp450:"P-450(3)"
;[596..598]:substance:"MC"
;[678..685]:quantitative-value:"417-418"
;[686..688]:quantitative-units:"nm"
(SENT
  (S
    (NP-SBJ (CC:[451..455] Both)
      (NP (JJ:[456..463] optical) (NN:[465..475] absorption))
      (CC:[476..479] and)
      (NML (NN:[480..483] EPR) (NNS:[484..491] studies)))
    (VP (VBP:[492..496] have)
      (VP (VBN:[497..502] shown)
        (SBAR (IN:[503..507] that)
          (S
            (NP-SBJ
              (NP (DT:[508..511] the) (JJ:[512..520] oxidized)
                  (NNS:[521..526] forms))
              (PP (IN:[527..529] of)
                (NP
                  (NP (NN:[530..538] P-450-LRB-1-RRB-))
                  (,:[538..539] ,)
                  (NP
                    (NP (NN:[541..549] P-450-LRB-2-RRB-))
                    (PRN (-LRB-:[550..551] -LRB-)
                      (PP (IN:[551..555] from)
                        (NP
                          (ADJP (NN:[556..558] PB) (HYPH:[558..559] -)
                                (VBN:[559..566] treated))
                          (NNS:[567..574] animals)))
                      (-RRB-:[574..575] -RRB-)))
                  (,:[575..576] ,) (CC:[577..580] and)
                  (NP
                    (NP (NN:[581..589] P-450-LRB-3-RRB-))
                    (PRN (-LRB-:[590..591] -LRB-)
                      (PP (IN:[591..595] from)
                        (NP
                          (ADJP (NN:[596..598] MC) (HYPH:[598..599] -)
                                (VBN:[599..606] treated))
                          (NNS:[607..614] animals)))
                      (-RRB-:[614..615] -RRB-))))))
            (VP (VBP:[616..619] are)
              (PP-PRD (IN:[621..623] in)
                (NP (DT:[624..627] the)
                  (NML (JJ:[628..631] low) (NN:[632..636] spin))
                  (NN:[637..642] state)))
              (,:[642..643] ,)
              (S-ADV
                (NP-SBJ (-NONE-:[643..643] *))
                (VP (VBG:[644..650] having)
                  (NP (DT:[651..652] a) (NN:[653..658] Soret)
                      (NN:[659..669] absorption) (NN:[670..674] peak))
                  (PP (IN:[675..677] at)
                    (NP
                      (QP (CD:[678..681] 417) (HYPH:[681..682] -)
                          (CD:[682..685] 418))
                      (NN:[686..688] nm))))))))))
    (.:[688..689] .)))

;sentence 6 Span:690..824
;Oxidized  P-448(1) (from both PB- and MC-treated animals), on the other hand,
;shows a  Soret peak at 393 nm and a weak band at 646 nm.
;[700..708]:cyp450:"P-448(1)"
;[720..722]:substance:"PB"
;[728..730]:substance:"MC"
;[791..794]:quantitative-value:"393"
;[795..797]:quantitative-units:"nm"
;[817..820]:quantitative-value:"646"
;[821..823]:quantitative-units:"nm"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[690..698] Oxidized) (NN:[700..708] P-448-LRB-1-RRB-))
      (PRN (-LRB-:[709..710] -LRB-)
        (PP (IN:[710..714] from)
          (NP (CC:[715..719] both)
            (NP
              (ADJP (NN:[720..722] PB) (HYPH:[722..723] -)
                (ADJP-2 (-NONE-:[723..723] *P*)))
              (NML-1 (-NONE-:[723..723] *P*)))
            (CC:[724..727] and)
            (NP
              (ADJP (NN:[728..730] MC) (HYPH:[730..731] -)
                (ADJP-2 (VBN:[731..738] treated)))
              (NML-1 (NNS:[739..746] animals)))))
        (-RRB-:[746..747] -RRB-)))
    (,:[747..748] ,)
    (PP (IN:[749..751] on)
      (NP (DT:[752..755] the) (JJ:[756..761] other) (NN:[762..766] hand)))
    (,:[766..767] ,)
    (VP (VBZ:[768..773] shows)
      (NP
        (NP
          (NP (DT:[774..775] a) (NN:[777..782] Soret) (NN:[783..787] peak))
          (PP-LOC (IN:[788..790] at)
            (NP (CD:[791..794] 393) (NN:[795..797] nm))))
        (CC:[798..801] and)
        (NP
          (NP (DT:[802..803] a) (JJ:[804..808] weak) (NN:[809..813] band))
          (PP-LOC (IN:[814..816] at)
            (NP (CD:[817..820] 646) (NN:[821..823] nm))))))
    (.:[823..824] .)))

;sentence 7 Span:825..1036
;This and EPR evidence indicate  that P-448(1) contains heme which is
;predominantly in the high spin state,  though EPR studies at low temperature
;indicate the presence of a small amount of  low spin ferric heme.
;[862..870]:cyp450:"P-448(1)"
;[880..884]:substance:"heme"
;[1024..1035]:substance:"ferric heme"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[825..829] This))
      (CC:[830..833] and)
      (NP (NN:[834..837] EPR) (NN:[838..846] evidence)))
    (VP (VBP:[847..855] indicate)
      (SBAR (IN:[857..861] that)
        (S
          (NP-SBJ (NN:[862..870] P-448-LRB-1-RRB-))
          (VP (NNS:[871..879] contains)
            (NP
              (NP (NN:[880..884] heme))
              (SBAR
                (WHNP-1 (WDT:[885..890] which))
                (S
                  (NP-SBJ-1 (-NONE-:[890..890] *T*))
                  (VP (VBZ:[891..893] is)
                    (PP-PRD
                      (ADVP (JJ:[894..907] predominantly))
                      (IN:[908..910] in)
                      (NP (DT:[911..914] the)
                        (NML (JJ:[915..919] high) (NN:[920..924] spin))
                        (NN:[925..930] state))))))))))
      (,:[930..931] ,)
      (SBAR-ADV (IN:[933..939] though)
        (S
          (NP-SBJ
            (NP (NN:[940..943] EPR) (NNS:[944..951] studies))
            (PP (IN:[952..954] at)
              (NP (JJ:[955..958] low) (NN:[959..970] temperature))))
          (VP (VBP:[971..979] indicate)
            (NP
              (NP (DT:[980..983] the) (NN:[984..992] presence))
              (PP (IN:[993..995] of)
                (NP
                  (NP (DT:[996..997] a) (JJ:[998..1003] small)
                      (NN:[1004..1010] amount))
                  (PP (IN:[1011..1013] of)
                    (NP
                      (NML (JJ:[1015..1018] low) (NN:[1019..1023] spin))
                       (JJ:[1024..1030] ferric) (NN:[1031..1035] heme))))))))))
    (.:[1035..1036] .)))

;sentence 8 Span:1037..1274
;The presence of tightly bound MC in P-448(1) purified from  MM-treated
;animals is reflected by characteristic absorption peaks in the  ultraviolet
;region, but this does not affect the absorption spectra in the Soret  and
;visible regions.
;[1067..1069]:substance:"MC"
;[1073..1081]:cyp450:"P-448(1)"
;[1097..1099]:substance:"MM"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (DT:[1037..1040] The) (NN:[1041..1049] presence))
        (PP (IN:[1050..1052] of)
          (NP
            (ADJP (RB:[1053..1060] tightly) (MD:[1061..1066] bound))
            (NN:[1067..1069] MC)))
        (PP-LOC (IN:[1070..1072] in)
          (NP
            (NP (NN:[1073..1081] P-448-LRB-1-RRB-))
            (VP (VBN:[1082..1090] purified)
              (NP (-NONE-:[1090..1090] *))
              (PP (IN:[1091..1095] from)
                (NP
                  (ADJP (NN:[1097..1099] MM) (HYPH:[1099..1100] -)
                        (VBN:[1100..1107] treated))
                  (NNS:[1108..1115] animals)))))))
      (VP (VBZ:[1116..1118] is)
        (VP (VBN:[1119..1128] reflected)
          (NP-2 (-NONE-:[1128..1128] *))
          (PP (IN:[1129..1131] by)
            (NP-LGS
              (NP (JJ:[1132..1146] characteristic) (NN:[1147..1157] absorption)
                  (NNS:[1158..1163] peaks))
              (PP (IN:[1164..1166] in)
                (NP (DT:[1167..1170] the) (NN:[1172..1183] ultraviolet)
                    (NN:[1184..1190] region))))))))
    (,:[1190..1191] ,) (CC:[1192..1195] but)
    (S
      (NP-SBJ (DT:[1196..1200] this))
      (VP (VBZ:[1201..1205] does) (RB:[1206..1209] not)
        (VP (VB:[1210..1216] affect)
          (NP (DT:[1217..1220] the) (NN:[1221..1231] absorption)
              (NN:[1232..1239] spectra))
          (PP-LOC (IN:[1240..1242] in)
            (NP (DT:[1243..1246] the)
              (NML
                (NML (NN:[1247..1252] Soret)
                  (NML-1 (-NONE-:[1252..1252] *P*)))
                (CC:[1254..1257] and)
                (NML (JJ:[1258..1265] visible)
                  (NML-1 (NNS:[1266..1273] regions)))))))))
    (.:[1273..1274] .)))

;sentence 9 Span:1275..1503
;Emulgen 913, a nonionic detergent, causes the conversion of  oxidized
;P-448(1) from the high to the low spin state, as evidenced by optical 
;absorption and EPR results; bound MC inhibits this conversion in a 
;noncompetitive way.
;[1275..1286]:substance:"Emulgen 913"
;[1299..1308]:substance:"detergent"
;[1345..1353]:cyp450:"P-448(1)"
;[1450..1452]:substance:"MC"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[1275..1282] Emulgen) (CD:[1283..1286] 913))
        (,:[1286..1287] ,)
        (NP (DT:[1288..1289] a) (JJ:[1290..1298] nonionic)
            (NN:[1299..1308] detergent)))
      (,:[1308..1309] ,)
      (VP (VBZ:[1310..1316] causes)
        (NP
          (NP (DT:[1317..1320] the) (NN:[1321..1331] conversion))
          (PP (IN:[1332..1334] of)
            (NP (VBN:[1336..1344] oxidized) (NN:[1345..1353] P-448-LRB-1-RRB-)))
          (PP (IN:[1354..1358] from)
            (NP (DT:[1359..1362] the) (JJ:[1363..1367] high)))
          (PP (TO:[1368..1370] to)
            (NP (DT:[1371..1374] the) (JJ:[1375..1378] low)
                (NN:[1379..1383] spin) (NN:[1384..1389] state))))
        (,:[1389..1390] ,)
        (SBAR (IN:[1391..1393] as)
          (S
            (NP-SBJ-2 (-NONE-:[1393..1393] *))
            (VP (JJ:[1394..1403] evidenced)
              (NP-2 (-NONE-:[1403..1403] *))
              (PP (IN:[1404..1406] by)
                (NP
                  (NP
                    (NML (JJ:[1407..1414] optical) (NN:[1416..1426] absorption))
                    (NML-1 (-NONE-:[1426..1426] *P*)))
                  (CC:[1427..1430] and)
                  (NP (NN:[1431..1434] EPR)
                    (NML-1 (NNS:[1435..1442] results))))))))))
    (::[1442..1443] ;)
    (S
      (NP-SBJ (VBN:[1444..1449] bound) (NN:[1450..1452] MC))
      (VP (VBZ:[1453..1461] inhibits)
        (NP (DT:[1462..1466] this) (NN:[1467..1477] conversion))
        (PP (IN:[1478..1480] in)
          (NP (DT:[1481..1482] a) (JJ:[1484..1498] noncompetitive)
              (NN:[1499..1502] way)))))
    (.:[1502..1503] .)))

;sentence 10 Span:1504..1776
;Binding of ethyl isocyanide to reduced P-450(1) and P-448(1)  results in the
;appearance of two Soret peaks in the 430 and 455 nm regions, the  relative
;intensities of which are dependent on pH. At any pH the 455 nm peak of 
;P-448(1) is always higher than that of P-450(1).
;[1515..1531]:substance:"ethyl isocyanide"
;[1543..1551]:cyp450:"P-450(1)"
;[1556..1564]:cyp450:"P-448(1)"
;[1618..1621]:quantitative-value:"430"
;[1626..1629]:quantitative-value:"455"
;[1630..1632]:quantitative-units:"nm"
;[1694..1696]:quantitative-name:"pH"
;[1705..1707]:quantitative-name:"pH"
;[1712..1715]:quantitative-value:"455"
;[1716..1718]:quantitative-units:"nm"
;[1728..1736]:cyp450:"P-448(1)"
;[1767..1775]:cyp450:"P-450(1)"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1504..1511] Binding))
      (PP (IN:[1512..1514] of)
        (NP (JJ:[1515..1520] ethyl) (NN:[1521..1531] isocyanide)))
      (PP (TO:[1532..1534] to)
        (NP
          (NP
            (ADJP-2 (JJ:[1535..1542] reduced))
            (NN:[1543..1551] P-450-LRB-1-RRB-))
          (CC:[1552..1555] and)
          (NP
            (ADJP-2 (-NONE-:[1555..1555] *P*))
            (NN:[1556..1564] P-448-LRB-1-RRB-)))))
    (VP (NNS:[1566..1573] results)
      (PP-CLR (IN:[1574..1576] in)
        (NP
          (NP (DT:[1577..1580] the) (NN:[1581..1591] appearance))
          (PP (IN:[1592..1594] of)
            (NP (CD:[1595..1598] two) (NN:[1599..1604] Soret)
                (NNS:[1605..1610] peaks)))
          (PP-LOC (IN:[1611..1613] in)
            (NP
              (NP (DT:[1614..1617] the)
                (NML
                  (NML
                    (NML (CD:[1618..1621] 430)
                      (NML-1 (-NONE-:[1621..1621] *P*)))
                    (NML-3 (-NONE-:[1621..1621] *P*)))
                  (CC:[1622..1625] and)
                  (NML
                    (NML (CD:[1626..1629] 455)
                      (NML-1 (NN:[1630..1632] nm)))
                    (NML-3 (NNS:[1633..1640] regions))))
                (,:[1640..1641] ,))
              (SBAR
                (WHNP-4
                  (NP (DT:[1642..1645] the) (JJ:[1647..1655] relative)
                      (NNS:[1656..1667] intensities))
                  (WHPP (IN:[1668..1670] of)
                    (WHNP (WDT:[1671..1676] which))))
                (S
                  (NP-SBJ-4 (-NONE-:[1676..1676] *T*))
                  (VP (VBP:[1677..1680] are)
                    (ADJP-PRD (JJ:[1681..1690] dependent)
                      (PP (IN:[1691..1693] on)
                        (NP (NN:[1694..1696] pH))))))))))))
    (.:[1696..1697] .))
  (S
    (PP (IN:[1698..1700] At)
      (NP (DT:[1701..1704] any) (NN:[1705..1707] pH)))
    (NP-SBJ
      (NP (DT:[1708..1711] the)
        (NML (CD:[1712..1715] 455) (NN:[1716..1718] nm))
        (NN:[1719..1723] peak))
      (PP (IN:[1724..1726] of)
        (NP (NN:[1728..1736] P-448-LRB-1-RRB-))))
    (VP (VBZ:[1737..1739] is)
      (ADVP (RB:[1740..1746] always))
      (ADJP-PRD
        (ADJP (JJR:[1747..1753] higher))
        (PP (IN:[1754..1758] than)
          (NP
            (NP (DT:[1759..1763] that))
            (PP (IN:[1764..1766] of)
              (NP (NN:[1767..1775] P-450-LRB-1-RRB-)))))))
    (.:[1775..1776] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1504..1776]::S:S:

;sentence 11 Span:1777..1949
;Benzphetamine and aniline,  added to oxidized P-450(1), cause Type I and Type
;II spectral changes,  respectively, but the magnitudes of the changes are
;small in both cases.
;[1777..1790]:substance:"Benzphetamine"
;[1795..1802]:substance:"aniline"
;[1823..1831]:cyp450:"P-450(1)"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[1777..1790] Benzphetamine) (CC:[1791..1794] and)
            (NN:[1795..1802] aniline)))
      (,:[1802..1803] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1803..1803] *))
        (VP (VBD:[1805..1810] added)
          (PP (TO:[1811..1813] to)
            (NP (JJ:[1814..1822] oxidized) (NN:[1823..1831] P-450-LRB-1-RRB-)))))
      (,:[1831..1832] ,)
      (VP (VBD:[1833..1838] cause)
        (NP
          (NP
            (NML (NN:[1839..1843] Type) (CD:[1844..1845] I))
            (NML-1 (-NONE-:[1845..1845] *P*)))
          (CC:[1846..1849] and)
          (NP
            (NML (NN:[1850..1854] Type) (CD:[1855..1857] II))
            (NML-1 (JJ:[1858..1866] spectral) (NNS:[1867..1874] changes))))
        (,:[1874..1875] ,)
        (ADVP (RB:[1877..1889] respectively))))
    (,:[1889..1890] ,) (CC:[1891..1894] but)
    (S
      (NP-SBJ
        (NP (DT:[1895..1898] the) (NNS:[1899..1909] magnitudes))
        (PP (IN:[1910..1912] of)
          (NP (DT:[1913..1916] the) (NNS:[1917..1924] changes))))
      (VP (VBP:[1925..1928] are)
        (ADJP-PRD (JJ:[1929..1934] small))
        (PP-LOC (IN:[1935..1937] in)
          (NP (DT:[1938..1942] both) (NNS:[1943..1948] cases)))))
    (.:[1948..1949] .)))

;sentence 12 Span:1950..2201
;The  Soret peak of oxidized P-448(1) at 393 nm is completely shifted to 420
;nm on  addition of aniline, resulting in a reverse Type I spectral change;
;acetanilide  causes the conversion of the Soret peak to the low spin state to
;only a slight  extent.
;[1978..1986]:cyp450:"P-448(1)"
;[1990..1993]:quantitative-value:"393"
;[1994..1996]:quantitative-units:"nm"
;[2022..2025]:quantitative-value:"420"
;[2026..2028]:quantitative-units:"nm"
;[2045..2052]:substance:"aniline"
;[2101..2112]:substance:"acetanilide"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (DT:[1950..1953] The) (NN:[1955..1960] Soret) (NN:[1961..1965] peak))
        (PP (IN:[1966..1968] of)
          (NP (JJ:[1969..1977] oxidized) (NN:[1978..1986] P-448-LRB-1-RRB-)))
        (PP (IN:[1987..1989] at)
          (NP (CD:[1990..1993] 393) (NN:[1994..1996] nm))))
      (VP (VBZ:[1997..1999] is)
        (VP
          (ADVP (RB:[2000..2010] completely))
          (VBN:[2011..2018] shifted)
          (NP-1 (-NONE-:[2018..2018] *))
          (PP (TO:[2019..2021] to)
            (NP (CD:[2022..2025] 420) (NN:[2026..2028] nm)))
          (PP (IN:[2029..2031] on)
            (NP
              (NP (NN:[2033..2041] addition))
              (PP (IN:[2042..2044] of)
                (NP (NN:[2045..2052] aniline)))))
          (,:[2052..2053] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[2053..2053] *))
            (VP (VBG:[2054..2063] resulting)
              (PP-CLR (IN:[2064..2066] in)
                (NP (DT:[2067..2068] a) (NN:[2069..2076] reverse)
                  (NML (NN:[2077..2081] Type) (CD:[2082..2083] I))
                  (JJ:[2084..2092] spectral) (NN:[2093..2099] change))))))))
    (::[2099..2100] ;)
    (S
      (NP-SBJ (NN:[2101..2112] acetanilide))
      (VP (VBZ:[2114..2120] causes)
        (NP
          (NP (DT:[2121..2124] the) (NN:[2125..2135] conversion))
          (PP (IN:[2136..2138] of)
            (NP (DT:[2139..2142] the) (NN:[2143..2148] Soret)
                (NN:[2149..2153] peak)))
          (PP (TO:[2154..2156] to)
            (NP (DT:[2157..2160] the)
              (NML (JJ:[2161..2164] low) (NN:[2165..2169] spin))
              (NN:[2170..2175] state))))
        (PP (TO:[2176..2178] to)
          (NP
            (ADVP (RB:[2179..2183] only))
            (DT:[2184..2185] a) (JJ:[2186..2192] slight)
             (NN:[2194..2200] extent)))))
    (.:[2200..2201] .)))

;sentence 13 Span:2202..2308
;The conversions caused by aniline and acetanilide are both inhibited by  the
;presence of tightly bound MC.
;[2228..2235]:substance:"aniline"
;[2240..2251]:substance:"acetanilide"
;[2305..2307]:substance:"MC"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[2202..2205] The) (NNS:[2206..2217] conversions))
      (VP (VBN:[2218..2224] caused)
        (NP (-NONE-:[2224..2224] *))
        (PP (IN:[2225..2227] by)
          (NP-LGS (NN:[2228..2235] aniline) (CC:[2236..2239] and)
                  (NN:[2240..2251] acetanilide)))))
    (VP (VBP:[2252..2255] are)
      (VP
        (ADVP (DT:[2256..2260] both))
        (VBN:[2261..2270] inhibited)
        (NP-1 (-NONE-:[2270..2270] *))
        (PP (IN:[2271..2273] by)
          (NP-LGS
            (NP (DT:[2275..2278] the) (NN:[2279..2287] presence))
            (PP (IN:[2288..2290] of)
              (NP
                (ADJP (RB:[2291..2298] tightly) (JJ:[2299..2304] bound))
                (NN:[2305..2307] MC)))))))
    (.:[2307..2308] .)))

;sentence 14 Span:2309..2402
;On the basis of these and other observations,  the spin state of these
;P-450's are discussed.
;[2380..2387]:cyp450:"P-450's"
(SENT
  (S
    (PP (IN:[2309..2311] On)
      (NP
        (NP (DT:[2312..2315] the) (NN:[2316..2321] basis))
        (PP (IN:[2322..2324] of)
          (NP
            (NP (DT:[2325..2330] these)
              (NML-2 (-NONE-:[2330..2330] *P*)))
            (CC:[2331..2334] and)
            (NP (JJ:[2335..2340] other)
              (NML-2 (NNS:[2341..2353] observations)))))))
    (,:[2353..2354] ,)
    (NP-SBJ-1
      (NP (DT:[2356..2359] the) (NN:[2360..2364] spin) (NN:[2365..2370] state))
      (PP (IN:[2371..2373] of)
        (NP (DT:[2374..2379] these) (NNS:[2380..2387] P-450's))))
    (VP (VBP:[2388..2391] are)
      (VP (VBN:[2392..2401] discussed)
        (NP-1 (-NONE-:[2401..2401] *))))
    (.:[2401..2402] .)))

;section 15 Span:2406..2449
;PMID: 6252201 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[2406..2410] PMID) (::[2410..2411] :) (CD:[2412..2419] 6252201)
        (-LRB-:[2420..2421] -LSB-) (NNP:[2421..2427] PubMed) (::[2428..2429] -)
        (VBN:[2430..2437] indexed) (IN:[2438..2441] for)
        (NNP:[2442..2449] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[2449..EOF] ]

(ORPH -RSB-)
